These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 17889968

  • 1. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
    Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ.
    Neurobiol Aging; 2009 May; 30(5):682-90. PubMed ID: 17889968
    [Abstract] [Full Text] [Related]

  • 2. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease.
    Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, Pratico D, Wallin A, Zetterberg H, Tsui WH, Rusinek H, Blennow K, de Leon MJ.
    J Alzheimers Dis; 2009 May; 16(2):351-62. PubMed ID: 19221425
    [Abstract] [Full Text] [Related]

  • 3. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.
    JAMA; 2009 Jul 22; 302(4):385-93. PubMed ID: 19622817
    [Abstract] [Full Text] [Related]

  • 4. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.
    Mol Psychiatry; 2004 Jul 22; 9(7):705-10. PubMed ID: 14699432
    [Abstract] [Full Text] [Related]

  • 5. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S, AIBL Research Group.
    J Alzheimers Dis; 2015 Jul 22; 48(1):175-87. PubMed ID: 26401938
    [Abstract] [Full Text] [Related]

  • 6. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
    Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR, Alzheimer's Disease Neuroimaging Initiative.
    Neurology; 2009 Jul 28; 73(4):294-301. PubMed ID: 19636049
    [Abstract] [Full Text] [Related]

  • 7. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK.
    J Alzheimers Dis; 2011 Jul 28; 25(4):583-94. PubMed ID: 21460434
    [Abstract] [Full Text] [Related]

  • 8. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
    Arch Gen Psychiatry; 2012 Jan 28; 69(1):98-106. PubMed ID: 22213792
    [Abstract] [Full Text] [Related]

  • 9. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
    Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM.
    Arch Neurol; 2009 May 28; 66(5):638-45. PubMed ID: 19433664
    [Abstract] [Full Text] [Related]

  • 10. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.
    Neurobiol Aging; 2006 Feb 28; 27(2):237-44. PubMed ID: 16399209
    [Abstract] [Full Text] [Related]

  • 11. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
    Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K.
    Lancet Neurol; 2009 Jul 28; 8(7):619-27. PubMed ID: 19523877
    [Abstract] [Full Text] [Related]

  • 12. [Patients with mild cognitive impairment and a reduced CSF Aβ₁₋₄₂ protein progress rapidly to Alzheimer's disease].
    Monge-Argilés JA, Sánchez-Payá J, Muñoz-Ruiz C, Pampliega-Pérez A, Gómez-López MJ, Rodríguez Borja E, Montoya-Gutiérrez J, Leiva-Santana C.
    Neurologia; 2012 Jan 28; 27(1):28-33. PubMed ID: 21621878
    [Abstract] [Full Text] [Related]

  • 13. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
    Jongbloed W, Kester MI, van der Flier WM, Veerhuis R, Scheltens P, Blankenstein MA, Teunissen CE.
    Alzheimers Dement; 2013 May 28; 9(3):276-83. PubMed ID: 23110867
    [Abstract] [Full Text] [Related]

  • 14. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.
    Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A.
    Arch Neurol; 2002 Nov 28; 59(11):1729-34. PubMed ID: 12433260
    [Abstract] [Full Text] [Related]

  • 15. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.
    Methods; 2012 Apr 28; 56(4):484-93. PubMed ID: 22503777
    [Abstract] [Full Text] [Related]

  • 16. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P.
    J Alzheimers Dis; 2012 Apr 28; 29(1):229-38. PubMed ID: 22232006
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Apr 28; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 18. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F, Mariano-Goulart D, Payoux P, Alzheimer’s Disease Neuroimaging Initiative (ADNI).
    Alzheimers Res Ther; 2017 Apr 26; 9(1):32. PubMed ID: 28441967
    [Abstract] [Full Text] [Related]

  • 19. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH, Cogo-Moreira H, Rabin JS, Black SE, Swardfager W, Alzheimer's Disease Neuroimaging Initiative.
    J Neurosci; 2019 Sep 11; 39(37):7428-7437. PubMed ID: 31350262
    [Abstract] [Full Text] [Related]

  • 20. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
    Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K.
    Acta Neurol Scand Suppl; 2003 Sep 11; 179():47-51. PubMed ID: 12603251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.